The Irish Medicines Board for the management of urinary incontinence in adults with neurogenic detrusor overactivity’s (NDO) decision is supported by the results of Phase III programme evaluating Botox.
The trial results demonstrated that the targeted injections of Botox into the bladder muscle showed reduction in the involuntary contractions and increase bladder capacity.
Allergan president for Europe, Africa and the Middle East Douglas Ingram said their task now is to work closely with the national health authorities to secure the relevant national licenses so that they can bring this valuable treatment option to patients, as quickly as possible.